Search results
Showing 1 to 15 of 34 results for semaglutide
Evidence-based recommendations on semaglutide (Wegovy) for managing overweight and obesity in adults.
In development Reference number: GID-TA11544 Expected publication date: 14 May 2026
Awaiting development Reference number: GID-TA10438 Expected publication date: TBC
Semaglutide for treating type 2 diabetes in people 10 to 17 years [TSID12249]
Topic prioritisation
NICE is unable to make a recommendation on semaglutide (Wegovy) for managing overweight and obesity in young people aged 12 to 17 years because Novo Nordisk did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA910
In development Reference number: GID-TA11477 Expected publication date: 12 August 2026
Semaglutide 7.2 mg single-dose device for managing overweight and obesity [ID6699]
Awaiting development Reference number: GID-TA11920 Expected publication date: TBC
Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]
In development Reference number: GID-TA11414 Expected publication date: 10 June 2026
Evidence-based recommendations on tirzepatide (Mounjaro) for managing overweight and obesity in adults.
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (HST31)
Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity and hyperphagia in Bardet-Biedl syndrome in people 6 years and over, only if they are between 6 and 17 years when treatment starts.
Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.
ID6611 Obesity, overweight - semaglutide (including review of TA875)
Awaiting development Reference number: GID-TA11851 Expected publication date: TBC
Our forward view highlights the topics we will prioritise in the coming year.